Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609932 · ClinicalTrials.gov registry record · Phase 1
Effect of IFN-γ on Innate Immune Cells
A Phase 1 study of Chronic Granulomatous Disease, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02609932: Completed Phase 1 study of Chronic Granulomatous Disease, sponsored by University of Colorado, Denver.
NCT02609932 is a Phase 1 study of Chronic Granulomatous Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 20 participants, below the 31-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02609932, a Phase 1 study of Chronic Granulomatous Disease, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune\*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.
Primary Outcome
Nox2 activity will be measured by DHR oxidation or Sod inhibitable cytochrome c reduction.
Conditions Studied
Interventions
- DRUG Administration of drug (Interferon-gamma 1-b) subcutaneously
Study Locations (1)
Colorado
- University of Colorado Denver, Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
What the finished NCT02609932 record still lists
NCT02609932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 31-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Chronic Granulomatous Disease appearing as the primary indexed condition, and to 1 intervention - of which Administration of drug (Interferon-gamma 1-b) subcutaneously is the first listed.
NCT02609932 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02609932 about?
NCT02609932 is a clinical study titled "Effect of IFN-γ on Innate Immune Cells". The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune\*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The i...
What is the current status of trial NCT02609932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-07. Estimated completion is 2019-02.
What conditions does trial NCT02609932 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease.
What interventions are being tested in trial NCT02609932?
The interventions under investigation include: Administration of drug (Interferon-gamma 1-b) subcutaneously (DRUG).
Who is sponsoring clinical trial NCT02609932?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02609932 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02609932's enrollment target sits among peer trials
20 6th of 10 higher than 4 of 10 other Chronic Granulomatous Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Granulomatous Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
RECRUITING · Phase 1
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
ACTIVE NOT RECRUITING · Phase 1
-
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
COMPLETED · Phase 1
-
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
ACTIVE NOT RECRUITING · Early Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia